Choksi Laboratories' shareholders reject preferential issue of convertible warrants
Choksi Laboratories · Healthcare Services
Key highlights
- Shareholders did not approve the convertible warrants issuance at EGM on October 17, 2026
- Promoters and proposed allottees abstained from voting on the resolution
- Company requests BSE to close the application for in-principle approval for the issue
Why it's rated notable: The filing states that shareholders did not approve the preferential warrant issue and the proposal will not proceed, but it gives no amount, so the level stays at medium.
Original filing
Announcement under Regulation 30 (LODR)-Preferential Issue
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other fundraise / allotment filings this fortnight
- Clean Max Enviro: Q2 results, NCDs up to Rs 3,000 crore approved, IFSC subsidiary planned
- Lloyds Metals and Energy Limited approves Q2 results, investment, and fundraising plans
- Lloyds Metals approves Q2 results, ₹625 crore TEIL investment and USD 300 million debt
- Mena Mani Industries approves Sept 2026 results, hotel venture and software expansion
- Sat Kartar Life Limited receives NSE approval for 5,50,000 convertible warrants issue
- CL Educate Limited approves ₹140 Cr fund raise and reports Q2 FY27 financials
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.